Orexo Logo

Orexo

Develops pharmaceuticals & digital health for opioid use disorder in the US market.

ORX | ST

Overview

Corporate Details

ISIN(s):
SE0000736415 (+2 more)
LEI:
549300LJ5CCWDPTK9Z08
Country:
Sweden
Address:
Box 303, 751 05 UPPSALA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orexo is an international, commercial-stage pharmaceutical company specializing in the development of improved pharmaceuticals based on proprietary drug delivery technologies. With a 30-year history, the company creates innovative treatment solutions for significant medical needs. A primary focus for Orexo is the US market, where it commercializes drugs and digital mental health programs for patients suffering from opioid use disorder (OUD) and adjacent diseases. Through its robust product pipeline, Orexo is committed to addressing major public health challenges, including the opioid crisis.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-21 18:00
Kallelse till extra bolagsstämma i Orexo AB (publ)
Swedish 44.5 KB
2024-10-24 08:00 Swedish 4.0 MB
2024-10-24 08:00 English 3.9 MB
2024-07-17 08:01 English 4.4 MB
2024-07-17 08:00 Swedish 4.4 MB
2024-07-16 20:00
Orexo shares new information on OX124, a high-dose naloxone rescue medication i…
English 187.5 KB
2024-07-16 20:00
Orexo delar ny information om OX124, ett högdosläkemedel vid opioidöverdos med …
Swedish 190.4 KB
2024-05-08 08:00 Swedish 3.9 MB
2024-05-08 08:00 English 4.2 MB
2024-04-26 17:30
Kommuniké från Orexo AB:s årsstämma den 26 april 2024
Swedish 135.7 KB
2024-04-26 17:30
Report from Orexo AB’s annual general meeting, 26 April 2024
English 144.2 KB
2024-03-28 08:01 Swedish 13.4 MB
2024-03-15 18:30
Rättelse: Kallelse till årsstämma i Orexo
Swedish 310.6 KB
2024-03-15 18:30
Correction: Notice of Annual General Meeting of Orexo
English 345.5 KB
2024-03-15 10:00
Notice of Annual General Meeting of Orexo
English 237.3 KB

Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orexo

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orexo via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-11 Nikolaj Arrild Sørensen Other Buy 2,460 35,178.00 SEK
2025-04-04 Nikolaj Arrild Sørensen Other Buy 3,500 47,530.00 SEK
2024-03-26 Fredrik Järrsten Other Buy 3,000 44,040.00 SEK
2023-11-24 Charlotte Vithlani Hansson Other Buy 3,000 44,640.00 SEK
2023-11-08 Fredrik Järrsten Other Buy 1,500 23,715.00 SEK
2023-02-24 Nikolaj Arrild Sørensen Other Buy 11,500 188,945.00 SEK
2023-01-27 Fredrik Järrsten Other Buy 4,500 79,695.00 SEK
2022-07-26 Michael Matly Other Buy 2,820 60,777.77 SEK
2022-07-21 Charlotte Vithlani Hansson Other Buy 3,000 61,500.00 SEK
2022-07-15 James Noble Other Buy 18,500 394,252.80 SEK

Peer Companies

BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America
BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea
003000
C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
Cambrex Logo
United States of America
CBM
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL

Talk to a Data Expert

Have a question? We'll get back to you promptly.